The company’s initial product in development is INT301, a new treatment for those who suffer peanut allergy. The product is intended to significantly raise the patients’ immune threshold beyond that which can trigger a potentially dangerous allergic reaction via accidental exposure. This additional protection is important for relieving the persistent anxiety that peanut allergic individuals can perceive, as small amounts of peanut protein can occasionally be present in foods that are thought to be peanut-free.
Peanut allergy is a life-threatening disease with only one approved medical treatment option, which may not be suitable for some peanut allergy sufferers due to side effects and potential safety issues. Avoidance of peanut consumption is typically practiced by affected individuals, coupled with reliance on antihistamines or epinephrine injection in the event of symptoms triggered by accidental exposure. Strict dietary avoidance is often expensive and hard to achieve and accidental exposure to peanut allergens is common. The resulting risk and anxiety for peanut allergy sufferers and their families can be significant and is a highly motivating force in seeking out therapy. There is a particularly high unmet need for pediatric peanut allergy sufferers who spend most of the day at school or elsewhere at a distance from immediate parental oversight.